In Russia began to use a vaccine against allergies to birch pollen
On the territory of the Russian Federation began to use an innovative tool to combat allergies to birch pollen
On the territory of the Russian Federation, the use of an innovative tool to combat allergies to birch pollen began. According to the statement of Deputy Prime Minister Tatyana Golikova, sounded at the IV International Forum of Nature-like Technologies at the Kurchatov Institute, the drug has received official registration and will be available from 2026.
Moreover, as Golikova noted, in the coming year, Russian citizens will have access to two additional personalized medicines under the compulsory medical insurance system.
Earlier, the Ministry of Health of Russia announced the registration of the domestic drug Allergard, intended for the prevention and treatment of allergic rhinoconjunctivitis.
The developer of this recombinant vaccine against birch pollen allergy and cross-food reactions was the Research Institute of Allergology and Immunology of the Federal Medical and Biological Agency (FMBA) of Russia. The head of FMBA, Veronika Skvortsova, previously emphasized the high safety and excellent tolerance of the Russian drug against allergies.
